NH vs. KTTA, SHPH, TENX, TBIO, VCNX, CVKD, HEPA, POAI, IBIO, and BFRI
Should you be buying NantHealth stock or one of its competitors? The main competitors of NantHealth include Pasithea Therapeutics (KTTA), Shuttle Pharmaceuticals (SHPH), Tenax Therapeutics (TENX), Telesis Bio (TBIO), Vaccinex (VCNX), Cadrenal Therapeutics (CVKD), Hepion Pharmaceuticals (HEPA), Predictive Oncology (POAI), iBio (IBIO), and Biofrontera (BFRI). These companies are all part of the "medical" sector.
NantHealth (NASDAQ:NH) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
NantHealth has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Pasithea Therapeutics has lower revenue, but higher earnings than NantHealth.
4.5% of NantHealth shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 61.3% of NantHealth shares are owned by company insiders. Comparatively, 14.1% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
NantHealth received 269 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 51.04% of users gave NantHealth an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote.
In the previous week, Pasithea Therapeutics had 2 more articles in the media than NantHealth. MarketBeat recorded 5 mentions for Pasithea Therapeutics and 3 mentions for NantHealth. Pasithea Therapeutics' average media sentiment score of 0.87 beat NantHealth's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.
Pasithea Therapeutics has a net margin of 0.00% compared to NantHealth's net margin of -94.67%. NantHealth's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.
Summary
NantHealth beats Pasithea Therapeutics on 7 of the 13 factors compared between the two stocks.
Get NantHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for NH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantHealth Competitors List
Related Companies and Tools
